{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    14,
    105
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "05",
        "name": "Amendment 05",
        "scope": {
          "id": "2c0564f6-be3b-4e6d-bd3f-fb664efdae4a",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "cbad9da7-531e-48c8-b9ec-c3292eeab195",
          "code": {
            "id": "06eca392-b274-47c4-986a-fb4c05c1dbce",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "802bd392-08b5-4aaa-96f5-ac051da8c322",
            "type": {
              "id": "deb83f80-f603-4a6d-b6f1-51e5dcb7c499",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary purpose of this amendment is to provide study visit scheduling flexibility by allowing optional phone visits to be done at week -4, week 2 and for the Continuous Glucose Monitoring visits (weeks 10/11 and weeks 22/23) during the 24 week double blinded short term treatment period.",
        "effectiveDate": "2016-05-18",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3",
          "ar_1_4"
        ],
        "previousVersion": "01",
        "newVersion": "02"
      },
      {
        "id": "amend_2",
        "number": "03",
        "name": "Amendment 03",
        "scope": {
          "id": "82d29fbe-2dc8-4efe-81dd-51ec9804b587",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "4d720315-dc85-4763-9f8e-31c9a1d850fd",
          "code": {
            "id": "5a2610ac-0d8c-4422-9ccf-071bd5056c4b",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "317f2d05-e438-4380-884f-0f99f3224272",
            "type": {
              "id": "86c5ad5d-3cb3-4d3b-b201-be0ee3df8607",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The primary purpose of the amendment was to modify the Inclusion and Exclusion Criteria based on feedback from the European Medicines Agency (EMA). Specifically, the EMA has endorsed removing the requirement that HbA1c may not drop more than 0.5% during the lead-in phase.",
        "effectiveDate": "2015-05-06",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2",
          "ar_2_3"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "01"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_4",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_3",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "Sweden",
        "instanceType": "Country",
        "code": "SE"
      },
      {
        "id": "country_2",
        "name": "Belgium",
        "instanceType": "Country",
        "code": "BE"
      },
      {
        "id": "country_3",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 2,
      "countryCount": 3,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2",
        "country_3"
      ],
      "regions": [
        "Ex-US",
        "Europe",
        "North America"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "05",
        "effectiveDate": "2016-05-18",
        "summary": "The primary purpose of this amendment is to provide study visit scheduling flexibility by allowing optional phone visits to be done at week -4, week 2 and for the Continuous Glucose Monitoring visits (weeks 10/11 and weeks 22/23) during the 24 week double blinded short term treatment period.",
        "previousVersion": "01",
        "newVersion": "02",
        "reasons": [
          "Operational",
          "Scientific",
          "Safety",
          "Administrative"
        ]
      },
      {
        "number": "03",
        "effectiveDate": "2015-05-06",
        "summary": "The primary purpose of the amendment was to modify the Inclusion and Exclusion Criteria based on feedback from the European Medicines Agency (EMA). Specifically, the EMA has endorsed removing the requirement that HbA1c may not drop more than 0.5% during the lead-in phase.",
        "previousVersion": "Original Protocol",
        "newVersion": "01",
        "reasons": [
          "Regulatory",
          "Scientific",
          "Operational"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "Sweden",
          "code": "SE"
        },
        {
          "name": "Belgium",
          "code": "BE"
        },
        {
          "name": "United States",
          "code": "US"
        }
      ],
      "regions": [
        "Ex-US",
        "Europe",
        "North America"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}